HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY M
This project will produce two bivalent dengue vaccine constructs based on adenovirus vectors. A tetravalent vaccine comprising two bivalent components will be tested in pre-clinical animal model systems.
Choose a quarter and click "Go."
| AWARD OVERVIEW |
| Award Number |
1U01AI078015-01 |
Funding Agency |
Department of Health and Human Services |
| Total Award Amount |
$1,616,449 |
Project Location - City |
Silver Spring |
| Award Date |
09/17/2009 |
Project Location - State |
MD |
| Project Status |
Completed |
Project Location - Zip |
20910-7500
|
| Jobs Reported |
0.00 |
Congressional District |
08 |
| Project Location - Country |
US |
|
|
Recipient Information
(Grants)
| Recipient Information (Grants) |
|
Recipient Name
|
HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY M |
| Recipient DUNS Number |
144676566
|
| Recipient Address |
6720-A ROCKLEDGE DR STE 100 |
| Recipient City |
BETHESDA |
| Recipient State |
Maryland |
| Recipient Zip |
20817-1834 |
| Recipient Congressional District |
08 |
| Recipient Country |
USA |
Required to Report Top 5
Highly Compensated Officials |
No |
Projects and Jobs Information
| Projects and Jobs Information |
| Project Title |
Tetravalent dengue vaccine based on complex adenovirus vectors |
| Project Status |
Completed |
| Final Project Report Submitted |
Yes |
| Project Activities Description |
Medical Research, General/Other |
| Quarterly Activities/Project Description |
This project has ended as of 8/31/2012.
Antigen coding sequences (pre-membrane and envelope) of all 4 dengue serotypes were optimized for human codon usage, and the optimized DNA
sequences were synthesized and cloned into plasmid vectors. Using these clones, two recombinant adenovirus vectors each expressing antigens from two dengue serotypes were constructed. This work was done with Genvec, the consortium partner, using its proprietary adenovirus vector containing modified hexon gene. The two bivalent vaccine constructs were characterized by DNA sequencing and antigen expression in infected 293 cells by indirect
immunofluorescence and western blot assays.
A murine immunogenicity study was completed in which the vaccine constructs were demonstrated to elicit neutralizing antibody response in vaccinated
mice. Vector seed stocks were prepared which will be useful in future cGMP manufacturing of vaccine constructs. Because these constructs were based on new, modified adenovirus vectors, we have also completed the necessary
process development and analytical development to aid in cGMP manufacture of
vaccines.
Sufficient material (GLP reagent grade) was produced for confirming immunogenicity in monkeys. A non-human primate study (funded separately) was started in October 2012. The constructs were immunogenic in rhesus monkeys; neutralizing antibodies to all 4 serotypes were demonstrated in animals
vaccinated with the tetravalent (mixture of two bivalent vaccines) dengue
vaccine.
This project started 16 months after the initial funding, necessitated by a
change in the consortium partner and revision to statement of work, all of
which was articulated to and approved by NIH. Project has made significant progress since then; however, cGMP manufacture of the vaccine could not be completed because a no-cost-extension to the grant was not granted. |
| Jobs Created |
0.00 |
| Description of Jobs Created |
N/A |
Purchaser Information
(Grants)
| Purchaser Information |
| Contracting Office ID |
Not Reported |
| Contracting Office Name |
Not Available |
| Contracting Office Region |
Not Available |
| TAS Major Program |
75-0900 |
| Award Information |
| Award Date |
09/17/2009 |
| Award Number |
1U01AI078015-01 |
| Order Number |
|
| Award Type |
Grants |
| Funding Agency ID |
75 |
| Funding Agency Name |
Department of Health and Human Services |
| Funding Office Name |
Not Available |
| Awarding Agency ID |
75 |
| Awarding Agency Name |
Department of Health and Human Services |
| Amount of Award |
$1,616,449 |
| Funds Invoiced/Received |
$924,851 |
| Expenditure Amount |
$924,851 |
| Infrastructure Expenditure Amount |
$0 |
| Infrastructure Purpose and Rationale |
Not Reported |
| Infrastructure Point of Contact Name |
Not Reported |
| Infrastructure Point of Contact Email |
Not Reported |
| Infrastructure Point of Contact Phone |
Not Reported |
| Infrastructure Point of Contact Address |
Not Reported |
| Infrastructure Point of Contact City |
Not Reported |
| Infrastructure Point of Contact State |
Not Reported |
| Infrastructure Point of Contact Zip |
Not Reported |
Product or Service Information
(Grants)
| Product or Service Information |
| Primary Activity Code |
H01 |
| Activity Description |
Medical Research, General/Other |
| Sub-Awards Information |
| Sub-awards to Organizations |
0 |
| Sub-award Amounts to Organizations |
$0 |
| Sub-Awards to Individuals |
0 |
| Sub-Award Amounts to Individuals |
$0 |
| Number of Sub-awards less than $25,000/award |
0 |
| Amount of Sub-awards less than $25,000/award |
$0 |
| Number of payments to vendors greater than $25,000 |
1 |
| Total Amount of payments to vendors greater than $25,000/award |
$587,829 |
| Number of payments to vendors less than $25,000/award |
85 |
| Total Amount of payments to vendors less than $25,000/award |
$73,877 |
Genvec, Inc - Award Number 1U01AI078015-01 - Genvec, Inc
| Award Number |
1U01AI078015-01 |
| Sub-Award Number |
N/A |
| Vendor DUNS Number |
232705690 |
| Vendor HQ Zip Code + 4 |
20878-4021 |
| Vendor Name |
Genvec, Inc |
| Product and Service Description |
Two Dengue Vector Seed Stocks with service agreement |
| Payment Amount |
$587,829 |
| Location Information |
| Latitude, Longitude |
39º 0' 14",
-77º 3' 15" |
| Congressional District |
08 |
| Address 1 |
Naval Medical Research Center |
| Address 2 |
503 Robert Grant Ave |
| City |
Silver Spring |
| County |
Montgomery |
| State |
MD |
| Zip |
20910-7500 |
|
 |